{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BXQ-350+-+Part+1+Dose+Escalation%3A+Safety+and+Tolerance",
    "query": {
      "intervention": "BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 3,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T23:14:00.495Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03967093",
      "title": "A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "BXQ-350",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 9,
      "start_date": "2019-04-15",
      "completion_date": "2020-01-17",
      "has_results": false,
      "last_update_posted_date": "2021-07-22",
      "last_synced_at": "2026-10-09T23:14:00.495Z",
      "location_count": 2,
      "location_summary": "Cincinnati, Ohio • Columbus, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03967093"
    },
    {
      "nct_id": "NCT02859857",
      "title": "Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "BXQ-350",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 86,
      "start_date": "2016-09-01",
      "completion_date": "2020-06-15",
      "has_results": false,
      "last_update_posted_date": "2021-07-22",
      "last_synced_at": "2026-10-09T23:14:00.495Z",
      "location_count": 4,
      "location_summary": "Lexington, Kentucky • Albuquerque, New Mexico • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02859857"
    },
    {
      "nct_id": "NCT04771897",
      "title": "A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Intrinsic Pontine Glioma",
        "Diffuse Midline Glioma, H3 K27M-Mutant"
      ],
      "interventions": [
        {
          "name": "BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance",
          "type": "DRUG"
        },
        {
          "name": "BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 10,
      "start_date": "2021-05-24",
      "completion_date": "2024-10-04",
      "has_results": false,
      "last_update_posted_date": "2024-12-20",
      "last_synced_at": "2026-10-09T23:14:00.495Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Cincinnati, Ohio • Columbus, Ohio",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04771897"
    }
  ]
}